Figure S4 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

This is a In Vitro Study study.

Key Points

Co-targeting bcl-xl and mcl-1 led to significant protein changes in models, indicating potential treatment synergy.
Combination treatment showed distinct effects on protein levels compared to single treatments, highlighting efficacy.
The approach included time-course assessment after 24 hours using various inhibitors for comparative analysis.
Findings suggest that dual targeting may enhance therapeutic outcomes in cancer with AR-V7 expression, emphasizing need for further studies.

Figure reveals protein level changes after treatments in AR-V7-expressing cancer models, suggesting synergy between therapies.

Figure S4 shows protein level changes after 24 hours of treatment with DMSO, A-1331852, S63845, or the combination of A-1331852 and S63845.

No takes yet. Share an insight, caveat, or question.

Brim et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share